BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Reports Second Quarter 2026 Financial Results

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

Related news

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

IRIXIRIDEX2026-08-18 20:05 EST

Iridex Reports Second Quarter 2026 Financial Results

PULMPulmatrix2026-08-13 12:15 EST

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

SMTISanara MedTech2026-08-11 20:10 EST

Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)

STIMNeuronetics2026-08-11 11:50 EST

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

TCMDTactile Systems Technology, Inc.2026-08-10 20:05 EST

Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results

TMCITreace Medical Concepts2026-08-07 11:05 EST

Treace Medical Concepts Reports Second Quarter 2026 Financial Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

APYXApyx Medical2026-08-06 20:05 EST

Apyx Medical Corporation Reports Second Quarter 2026 Financial Results

AORTArtivion2026-08-06 20:05 EST

Artivion Reports Second Quarter 2026 Financial Results

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-07-29 20:05 EST

Pulmonx Reports Second Quarter 2026 Financial Results

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

LUNGPulmonx2026-07-15 20:05 EST

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Stock data

Close
2.07 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States